Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Hemoglobin Testing Market by Technology (Chromatography, Immunoassay, Others) and by End User (Hospitals, Research Centers, Laboratories): Global Opportunity Analysis and Industry Forecast, 2023-2032

A03204

Pages: NA

Charts: NA

Tables: NA

Hemoglobin is a protein found in the red blood cells (RBCs) that carries out oxygen transportation throughout the body. Hemoglobin tests are carried out to measure the amount of hemoglobin present in the blood. These tests are usually performed during complete blood count as a routine health checkup or to determine the presence of any disease, which could occur due to low count of RBCs. Patients commonly undergo hemoglobin test due to reasons such as fatigue, poor health, or unexplained weight loss. The centralized hemoglobin testing methods are useful for the diagnosis of diabetes and anemia.

In home care testing, the laboratories send a professional person to the patients doorstep for blood sample collection and there is no need to visit laboratories or hospitals for tests. After the tests are conducted, the results are electronically sent back to the patient.

As most patients prefer home care testing to laboratories, there is growth in demand for direct-to-consumer testing, which is a major factor that drives the market growth. Moreover, the emergence of advanced techniques has improved the ease of testing and provides quick test results. Hence, the development of advanced hemoglobin testing devices is further expected to boost the market growth during the forecast period. However, high cost and maintenance associated with hemoglobin testing may hinder the market growth.

The global hemoglobin testing market is segmented based on technology, end user, and geography. Based on technology, it is divided into chromatography, immunoassay, and other. Based on end user, it is categorized into hospitals, research centers, and laboratories. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Comprehensive competitive analysis and profiles of major players, such as Abbott Laboratories, ACON Laboratories, Alere, Bayer Medical Care, Bio-Rad Laboratories, Danaher, EKF Diagnostics Holdings, F. Hoffmann-La Roche, Siemens Healthcare, and Thermo Fisher Scientific, are also provided in this report.

Key Benefits

  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the global hemoglobin testing market to identify the prevailing market opportunities.
  • The projections in this report are made by analyzing the current trends and future market potential in terms of value.
  • Competitive intelligence helps to understand the competitive scenario across the geographies.
  • An in-depth analysis of current research and clinical developments within market is provided with key dynamic factors that help understand the market behavior.

 Key Market Segments

  • By Technology
    • Chromatography
    • Immunoassay
    • Others
  • By End User
    • Hospitals
    • Research Centers
    • Laboratories
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • ACON Laboratories
  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • EKF Diagnostics Holdings
  • Bio-Rad Laboratories
  • Abbott Laboratories
  • F. Hoffmann-La Roche
  • Bayer Medical Care
  • Alere
  • Siemens Healthcare

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: HEMOGLOBIN TESTING MARKET, BY TECHNOLOGY

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Technology

    • 4.2. Chromatography

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Immunoassay

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Others

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: HEMOGLOBIN TESTING MARKET, BY END USER

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By End User

    • 5.2. Hospitals

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Research Centers

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Laboratories

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: HEMOGLOBIN TESTING MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Technology

      • 6.2.3. Market Size and Forecast, By End User

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Hemoglobin Testing Market

        • 6.2.5.1. Market Size and Forecast, By Technology
        • 6.2.5.2. Market Size and Forecast, By End User

      • 6.2.6. Canada Hemoglobin Testing Market

        • 6.2.6.1. Market Size and Forecast, By Technology
        • 6.2.6.2. Market Size and Forecast, By End User

      • 6.2.7. Mexico Hemoglobin Testing Market

        • 6.2.7.1. Market Size and Forecast, By Technology
        • 6.2.7.2. Market Size and Forecast, By End User

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Technology

      • 6.3.3. Market Size and Forecast, By End User

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Hemoglobin Testing Market

        • 6.3.5.1. Market Size and Forecast, By Technology
        • 6.3.5.2. Market Size and Forecast, By End User

      • 6.3.6. Germany Hemoglobin Testing Market

        • 6.3.6.1. Market Size and Forecast, By Technology
        • 6.3.6.2. Market Size and Forecast, By End User

      • 6.3.7. Italy Hemoglobin Testing Market

        • 6.3.7.1. Market Size and Forecast, By Technology
        • 6.3.7.2. Market Size and Forecast, By End User

      • 6.3.8. Spain Hemoglobin Testing Market

        • 6.3.8.1. Market Size and Forecast, By Technology
        • 6.3.8.2. Market Size and Forecast, By End User

      • 6.3.9. UK Hemoglobin Testing Market

        • 6.3.9.1. Market Size and Forecast, By Technology
        • 6.3.9.2. Market Size and Forecast, By End User

      • 6.3.10. Russia Hemoglobin Testing Market

        • 6.3.10.1. Market Size and Forecast, By Technology
        • 6.3.10.2. Market Size and Forecast, By End User

      • 6.3.11. Rest Of Europe Hemoglobin Testing Market

        • 6.3.11.1. Market Size and Forecast, By Technology
        • 6.3.11.2. Market Size and Forecast, By End User

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Technology

      • 6.4.3. Market Size and Forecast, By End User

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Hemoglobin Testing Market

        • 6.4.5.1. Market Size and Forecast, By Technology
        • 6.4.5.2. Market Size and Forecast, By End User

      • 6.4.6. Japan Hemoglobin Testing Market

        • 6.4.6.1. Market Size and Forecast, By Technology
        • 6.4.6.2. Market Size and Forecast, By End User

      • 6.4.7. India Hemoglobin Testing Market

        • 6.4.7.1. Market Size and Forecast, By Technology
        • 6.4.7.2. Market Size and Forecast, By End User

      • 6.4.8. South Korea Hemoglobin Testing Market

        • 6.4.8.1. Market Size and Forecast, By Technology
        • 6.4.8.2. Market Size and Forecast, By End User

      • 6.4.9. Australia Hemoglobin Testing Market

        • 6.4.9.1. Market Size and Forecast, By Technology
        • 6.4.9.2. Market Size and Forecast, By End User

      • 6.4.10. Thailand Hemoglobin Testing Market

        • 6.4.10.1. Market Size and Forecast, By Technology
        • 6.4.10.2. Market Size and Forecast, By End User

      • 6.4.11. Malaysia Hemoglobin Testing Market

        • 6.4.11.1. Market Size and Forecast, By Technology
        • 6.4.11.2. Market Size and Forecast, By End User

      • 6.4.12. Indonesia Hemoglobin Testing Market

        • 6.4.12.1. Market Size and Forecast, By Technology
        • 6.4.12.2. Market Size and Forecast, By End User

      • 6.4.13. Rest of Asia Pacific Hemoglobin Testing Market

        • 6.4.13.1. Market Size and Forecast, By Technology
        • 6.4.13.2. Market Size and Forecast, By End User

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Technology

      • 6.5.3. Market Size and Forecast, By End User

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Hemoglobin Testing Market

        • 6.5.5.1. Market Size and Forecast, By Technology
        • 6.5.5.2. Market Size and Forecast, By End User

      • 6.5.6. South Africa Hemoglobin Testing Market

        • 6.5.6.1. Market Size and Forecast, By Technology
        • 6.5.6.2. Market Size and Forecast, By End User

      • 6.5.7. Saudi Arabia Hemoglobin Testing Market

        • 6.5.7.1. Market Size and Forecast, By Technology
        • 6.5.7.2. Market Size and Forecast, By End User

      • 6.5.8. UAE Hemoglobin Testing Market

        • 6.5.8.1. Market Size and Forecast, By Technology
        • 6.5.8.2. Market Size and Forecast, By End User

      • 6.5.9. Argentina Hemoglobin Testing Market

        • 6.5.9.1. Market Size and Forecast, By Technology
        • 6.5.9.2. Market Size and Forecast, By End User

      • 6.5.10. Rest of LAMEA Hemoglobin Testing Market

        • 6.5.10.1. Market Size and Forecast, By Technology
        • 6.5.10.2. Market Size and Forecast, By End User

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Abbott Laboratories

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. ACON Laboratories

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Alere

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Bayer Medical Care

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Bio-Rad Laboratories

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Danaher Corporation

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. EKF Diagnostics Holdings

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. F. Hoffmann-La Roche

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Siemens Healthcare

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Thermo Fisher Scientific Inc.

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL HEMOGLOBIN TESTING MARKET, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL HEMOGLOBIN TESTING MARKET FOR CHROMATOGRAPHY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL HEMOGLOBIN TESTING MARKET FOR IMMUNOASSAY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL HEMOGLOBIN TESTING MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL HEMOGLOBIN TESTING MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL HEMOGLOBIN TESTING MARKET FOR HOSPITALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL HEMOGLOBIN TESTING MARKET FOR RESEARCH CENTERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL HEMOGLOBIN TESTING MARKET FOR LABORATORIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL HEMOGLOBIN TESTING MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. NORTH AMERICA HEMOGLOBIN TESTING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. NORTH AMERICA HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 12. NORTH AMERICA HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 13. U.S. HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 14. U.S. HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 15. CANADA HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 16. CANADA HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 17. MEXICO HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 18. MEXICO HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 19. EUROPE HEMOGLOBIN TESTING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 20. EUROPE HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 21. EUROPE HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 22. FRANCE HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 23. FRANCE HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 24. GERMANY HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 25. GERMANY HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 26. ITALY HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 27. ITALY HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 28. SPAIN HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 29. SPAIN HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 30. UK HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 31. UK HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 32. RUSSIA HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 33. RUSSIA HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 34. REST OF EUROPE HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 35. REST OF EUROPE HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 36. ASIA-PACIFIC HEMOGLOBIN TESTING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 37. ASIA-PACIFIC HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 38. ASIA-PACIFIC HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 39. CHINA HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 40. CHINA HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 41. JAPAN HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 42. JAPAN HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 43. INDIA HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 44. INDIA HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 45. SOUTH KOREA HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 46. SOUTH KOREA HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 47. AUSTRALIA HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 48. AUSTRALIA HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 49. THAILAND HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 50. THAILAND HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 51. MALAYSIA HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 52. MALAYSIA HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 53. INDONESIA HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 54. INDONESIA HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 55. REST OF ASIA PACIFIC HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 56. REST OF ASIA PACIFIC HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 57. LAMEA HEMOGLOBIN TESTING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 58. LAMEA HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 59. LAMEA HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 60. BRAZIL HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 61. BRAZIL HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 62. SOUTH AFRICA HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 63. SOUTH AFRICA HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 64. SAUDI ARABIA HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 65. SAUDI ARABIA HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 66. UAE HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 67. UAE HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 68. ARGENTINA HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 69. ARGENTINA HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 70. REST OF LAMEA HEMOGLOBIN TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 71. REST OF LAMEA HEMOGLOBIN TESTING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 72. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 73. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 74. ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 75. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 76. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 77. ACON LABORATORIES: KEY EXECUTIVES
  • TABLE 78. ACON LABORATORIES: COMPANY SNAPSHOT
  • TABLE 79. ACON LABORATORIES: OPERATING SEGMENTS
  • TABLE 80. ACON LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 81. ACON LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 82. ALERE: KEY EXECUTIVES
  • TABLE 83. ALERE: COMPANY SNAPSHOT
  • TABLE 84. ALERE: OPERATING SEGMENTS
  • TABLE 85. ALERE: PRODUCT PORTFOLIO
  • TABLE 86. ALERE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 87. BAYER MEDICAL CARE: KEY EXECUTIVES
  • TABLE 88. BAYER MEDICAL CARE: COMPANY SNAPSHOT
  • TABLE 89. BAYER MEDICAL CARE: OPERATING SEGMENTS
  • TABLE 90. BAYER MEDICAL CARE: PRODUCT PORTFOLIO
  • TABLE 91. BAYER MEDICAL CARE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 92. BIO-RAD LABORATORIES: KEY EXECUTIVES
  • TABLE 93. BIO-RAD LABORATORIES: COMPANY SNAPSHOT
  • TABLE 94. BIO-RAD LABORATORIES: OPERATING SEGMENTS
  • TABLE 95. BIO-RAD LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 96. BIO-RAD LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 97. DANAHER CORPORATION: KEY EXECUTIVES
  • TABLE 98. DANAHER CORPORATION: COMPANY SNAPSHOT
  • TABLE 99. DANAHER CORPORATION: OPERATING SEGMENTS
  • TABLE 100. DANAHER CORPORATION: PRODUCT PORTFOLIO
  • TABLE 101. DANAHER CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 102. EKF DIAGNOSTICS HOLDINGS: KEY EXECUTIVES
  • TABLE 103. EKF DIAGNOSTICS HOLDINGS: COMPANY SNAPSHOT
  • TABLE 104. EKF DIAGNOSTICS HOLDINGS: OPERATING SEGMENTS
  • TABLE 105. EKF DIAGNOSTICS HOLDINGS: PRODUCT PORTFOLIO
  • TABLE 106. EKF DIAGNOSTICS HOLDINGS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 107. F. HOFFMANN-LA ROCHE: KEY EXECUTIVES
  • TABLE 108. F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT
  • TABLE 109. F. HOFFMANN-LA ROCHE: OPERATING SEGMENTS
  • TABLE 110. F. HOFFMANN-LA ROCHE: PRODUCT PORTFOLIO
  • TABLE 111. F. HOFFMANN-LA ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 112. SIEMENS HEALTHCARE: KEY EXECUTIVES
  • TABLE 113. SIEMENS HEALTHCARE: COMPANY SNAPSHOT
  • TABLE 114. SIEMENS HEALTHCARE: OPERATING SEGMENTS
  • TABLE 115. SIEMENS HEALTHCARE: PRODUCT PORTFOLIO
  • TABLE 116. SIEMENS HEALTHCARE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 117. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES
  • TABLE 118. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  • TABLE 119. THERMO FISHER SCIENTIFIC INC.: OPERATING SEGMENTS
  • TABLE 120. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
  • TABLE 121. THERMO FISHER SCIENTIFIC INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL HEMOGLOBIN TESTING MARKET SEGMENTATION
  • FIGURE 2. GLOBAL HEMOGLOBIN TESTING MARKET
  • FIGURE 3. SEGMENTATION HEMOGLOBIN TESTING MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN HEMOGLOBIN TESTING MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALHEMOGLOBIN TESTING MARKET
  • FIGURE 11. HEMOGLOBIN TESTING MARKET SEGMENTATION, BY BY TECHNOLOGY
  • FIGURE 12. HEMOGLOBIN TESTING MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. HEMOGLOBIN TESTING MARKET FOR IMMUNOASSAY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. HEMOGLOBIN TESTING MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. HEMOGLOBIN TESTING MARKET SEGMENTATION, BY BY END USER
  • FIGURE 16. HEMOGLOBIN TESTING MARKET FOR HOSPITALS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. HEMOGLOBIN TESTING MARKET FOR RESEARCH CENTERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. HEMOGLOBIN TESTING MARKET FOR LABORATORIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 20. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 21. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 22. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 23. COMPETITIVE DASHBOARD
  • FIGURE 24. COMPETITIVE HEATMAP: HEMOGLOBIN TESTING MARKET
  • FIGURE 25. TOP PLAYER POSITIONING, 2024
  • FIGURE 26. ABBOTT LABORATORIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 27. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 28. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 29. ACON LABORATORIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 30. ACON LABORATORIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 31. ACON LABORATORIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 32. ALERE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 33. ALERE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 34. ALERE: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 35. BAYER MEDICAL CARE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 36. BAYER MEDICAL CARE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 37. BAYER MEDICAL CARE: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 38. BIO-RAD LABORATORIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 39. BIO-RAD LABORATORIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 40. BIO-RAD LABORATORIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 41. DANAHER CORPORATION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 42. DANAHER CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 43. DANAHER CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 44. EKF DIAGNOSTICS HOLDINGS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 45. EKF DIAGNOSTICS HOLDINGS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 46. EKF DIAGNOSTICS HOLDINGS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 47. F. HOFFMANN-LA ROCHE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 48. F. HOFFMANN-LA ROCHE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 49. F. HOFFMANN-LA ROCHE: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 50. SIEMENS HEALTHCARE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 51. SIEMENS HEALTHCARE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 52. SIEMENS HEALTHCARE: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 53. THERMO FISHER SCIENTIFIC INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 54. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 55. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Hemoglobin Testing Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved